Dermata Therapeutics, INC 8-K filings

Dermata Therapeutics, Inc. announced the anticipated launch date for its first commercial product, Tome Foundational Treatment, set for August 25, 2026.

Dermata Therapeutics shareholders approved key proposals including an equity plan expansion and warrant repricing.

Dermata Therapeutics announced its strategic shift to direct-to-consumer skincare with the launch of its 'Tome' brand and reported Q1 2026 financial results, including $2.0 million in net proceeds from ATM financing.

Dermata Therapeutics announced a strategic pivot to direct-to-consumer skincare products under the new brand Tome, alongside reporting its financial results for the year ended December 31, 2025, and securing $15.4 million in financing.

Mary Fisher has resigned from Dermata Therapeutics' Board of Directors, effective March 31, 2026, due to a new employer policy.

Dermata Therapeutics, Inc. announced a change in its independent registered public accounting firm, dismissing Baker Tilly US, LLP and appointing CBIZ CPAs P.C., following audit reports that included a 'going concern' explanatory paragraph.

Dermata Therapeutics, Inc. has increased the maximum aggregate offering amount of its common stock under its At The Market offering agreement by an additional $705,000.

Dermata Therapeutics announced a private placement raising $4.1 million upfront, with potential for an additional $8.3 million from warrant exercises, to fund general corporate purposes and product development.

Dermata Therapeutics, Inc. has terminated its license agreement with Villani, Inc., signaling a strategic pivot towards over-the-counter skin care treatments and away from its investigational drug pipeline.

Dermata Therapeutics announced a strategic shift to over-the-counter skincare, planning its first product launch in mid-2026, alongside reporting third-quarter 2025 financial results.

Dermata Therapeutics, Inc. increased its At-The-Market offering capacity by an additional $1.79 million, bringing the total potential raise to over $3.45 million.

Dermata Therapeutics presented positive clinical data for its XYNGARI (DMT310) Phase 3 STAR-1 trial, demonstrating statistically significant improvements in acne treatment.

Dermata Therapeutics, Inc. announced a strategic shift to prioritize over-the-counter pharmaceutical dermatology products, withdrawing its investigational new drug application for XYNGARI.

Dermata Therapeutics, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, avoiding delisting.

Dermata Therapeutics announced positive Phase 3 clinical trial data for XYNGARI in acne and reported second-quarter 2025 financial results, including an $8.8 million capital raise.

Dermata Therapeutics, Inc. will implement a one-for-10 reverse stock split of its common stock effective August 1, 2025, to adjust its share price and maintain Nasdaq listing compliance.

Shareholders have approved the election of directors, auditor ratification, and critical proposals for warrant issuances and a reverse stock split, providing the Board flexibility for future capital structure adjustments.

Dermata Therapeutics, Inc. has received an exception from Nasdaq until August 14, 2025, to regain compliance with the minimum bid price requirement, following a prior delisting notice.

Dermata Therapeutics, Inc. has appointed Baker Tilly US, LLP as its new independent registered public accounting firm, succeeding Moss Adams LLP following a merger, while noting Moss Adams' previous audit reports included a going concern uncertainty.

Dermata Therapeutics announces the initiation of drug product manufacturing for the XYNGARI Phase 3 STAR-2 trial, with expected topline results in the first half of 2027 and a potential NDA filing in the first half of 2028.

Dermata Therapeutics has regained compliance with Nasdaq's stockholders equity requirement but is now facing potential delisting due to non-compliance with the minimum bid price rule.

Dermata Therapeutics reports positive topline results from its XYNGARI Phase 3 STAR-1 clinical trial and raises $8.8 million in gross proceeds during Q1 2025.

Dermata Therapeutics announces positive topline results from its Phase 3 STAR-1 trial, showing XYNGARI achieved statistically significant differences from placebo in acne treatment efficacy as early as week 4.

Dermata Therapeutics announced a definitive agreement for the immediate exercise of outstanding warrants, resulting in $6.2 million in gross proceeds.

Dermata Therapeutics' XYNGARI met all primary endpoints in its first pivotal Phase 3 trial for moderate-to-severe acne, showing statistically significant improvement compared to placebo.

Dermata Therapeutics received a notification from Nasdaq regarding non-compliance with minimum stockholders' equity requirements, potentially leading to delisting.

Dermata Therapeutics reports full year 2024 financial results and provides a corporate update, highlighting progress on clinical trials and collaborations.

Dermata Therapeutics has successfully completed a $2.55 million private placement to support its research, clinical trials, and corporate development.

Dermata Therapeutics and Revance Therapeutics have entered into a clinical trial collaboration to evaluate a novel topical treatment for excessive underarm sweating using Dermata's Xyngari and Revance's Daxxify.

Dermata Therapeutics reported progress on its Phase 3 clinical trial for DMT310, raised $5.1 million in Q3 2024, and anticipates topline results in early 2025.